DLC1 and neoplasm: However, the combined inhibition of AKT inhibition (AKTi) + SRC inhibition (SRCi; by mk-2206 and saracatinib, respectively) can inhibit these phosphorylation activities and reactivate the tumor suppressor activity of DLC1 stabilized by EZH2i4.